BXCL501 for Pediatric Schizophrenia and Bipolar Agitation

"Currently, there are 110 clinical trials evaluating the efficacy of BXCL501 with 23 studies in their last phase. Most of these tests take place in Karachi, Sindh though there exist 207 sites across the world running this medication's research."

"This schizophrenia study requires 140 minors between the ages of 10 and 17. Inclusion criteria include a total score of at least 14 on the PANSS Excited Component (PEC) during screening and baseline, an agreement to use reliable birth control methods, as well as a score greater than 4 on one or more PEC items at Baseline."

"At the moment, this clinical trial is being conducted at 6 different sites. These can be found in Orem, Atlanta and Hialeah as well as 3 other cities. To reduce travel requirements for participants it would make sense to pick a clinic that's closest to your location if you enroll."

"Indeed, according to clinicaltrials.gov, this research initiative is actively enrolling participants; its initial posting was on August 27th 2021 and the most recent update was September 26th 2022. The study seeks 140 volunteers at 6 separate facilities."

"BXCL501 is a therapeutic agent used to manage the unsettling symptoms of diseases like ventilations, mechanical, and cyclic vomiting syndrome."

"Due to the limited amount of evidence available for its safety and efficacy, BXCL501 received a score of 1."

"Affirmative. This trial is looking for volunteers, and the information found on clinicaltrials.gov confirms this fact. It was first posted in August of 2021 and its most recent update was from September 2022. The experiment needs 140 patients to be recruited from 6 different research centres."

"This trial is targeting individuals aged 10 to 17. On clinicaltrials.gov, there are 367 studies open for minors and 911 trials available to senior citizens above 65 years of age."